Piperidine-3-carbonitrile hydrochloride

Catalog No.: 
ACOGAX745
CAS No.: 
1199773-75-5
Molecular Formula: 
C6H11ClN2
Molecular Weight: 
146.62
Piperidine-3-carbonitrile hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$55.00In stockIn stock
5g95%$158.00In stockIn stock
10g95%$263.00In stockIn stock

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NamePiperidine-3-carbonitrile hydrochloride
IUPAC Namepiperidine-3-carbonitrile hydrochloride
MDL No.MFCD09037929
Molecular FormulaC6H11ClN2
Molecular Weight146.62
SMILESN#CC1CNCCC1.[H]Cl
InChI KeyUGNVDGLCOHDISF-UHFFFAOYSA-N
SynonymPIPERIDINE-3-CARBONITRILE HYDROCHLORIDE | 1199773-75-5 | 828300-57-8 | piperidine-3-carbonitrile;hydrochloride | 3-Cyano-piperidine hydroc... | 3-Piperidinecarbonitrile, hydrochloride (1:1) | PIPERIDINE-3-CARBONITRILE HCL | 3-Cyanopiperidine hydrochloride | MFCD09037929 |
CAS No.1199773-75-5
PubChem CID53400639

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P305+P351+P338

Synthetic Route by SureRoute

1. ACOGAX745 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHNGM745 route compound structure diagram
    ACHNGM74591419-53-3In Stock
  2. Then
  3. ACOGAX745 route product structure diagram
    ACOGAX7451199773-75-5In Stock
Inquiry

2. ACOGAX745 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHICA426 route compound structure diagram
    ACHICA426100-54-9In Stock
  2. Then
  3. ACOGAX745 route product structure diagram
    ACOGAX7451199773-75-5In Stock
Inquiry

3. ACOGAX745 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLWSV429 route compound structure diagram
    ACLWSV429885069-22-7In Stock
  2. Then
  3. ACOGAX745 route product structure diagram
    ACOGAX7451199773-75-5In Stock
Inquiry

Comments (0)